Inhibition of Anti-Gal IgG Binding to Porcine Endothelial Cells by Synthetic Oligosaccharides
Overview
Affiliations
Rejection of pig-to-human or pig-to-primate xenografts is mediated by the natural anti-Gal antibody, which interacts with alpha-galactosyl epitopes (i.e., Gal alpha1-3Gal beta1-4GlcNAc-R) abundantly expressed on porcine cells. The objective of this study was to determine the ability of various synthetic oligosaccharides to inhibit the binding of anti-Gal IgG molecules to porcine endothelial cells in vitro. Such inhibition ultimately may help to reduce or to prevent the in vivo antibody-dependent cell cytotoxicity (ADCC) reaction. In the absence of complement-mediated hyperacute rejection, the ADCC induced by anti-Gal IgG molecules is likely to cause the chronic rejection of xenografts. The synthetic free alpha-galactosyl epitope (Gal alpha1-3Gal beta1-4GlcNAc) was found to be 300-fold more effective than melibiose or alpha-methyl galactoside in inhibiting anti-Gal binding to porcine endothelial cells, and to prevent >90% of the antibody binding at a concentration of 1 mM. The disaccharide Gal alpha1-3Gal was ten-fold less effective than the free alpha-galactosyl epitope. Accordingly, the affinity of the disaccharide to anti-Gal, as measured by equilibrium dialysis, was seven-fold lower than that of the trisaccharide. The effective concentration of oligosaccharides inhibiting anti-Gal is independent of the antibody affinity, but is dependent on the concentration of the antibody. Based on the small difference in affinity between Gal alpha1-3Gal beta1-4GlcNAc and Gal alpha1-3Gal beta1-4GIc, and the large difference in the price of N-acetyllactosamine vs. lactose, it is suggested that lactose may be considered as an appropriate starting material for synthesizing large amounts of a trisaccharide that effectively neutralizes anti-Gal.
Montoya A, Gil E, Vinales I, Estevao I, Taboada P, Torrico M Carbohydr Res. 2024; 536:109015.
PMID: 38198982 PMC: 11366264. DOI: 10.1016/j.carres.2023.109015.
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy.
Hinterholzer A, Moises J, Regl C, Schwap S, Rapp E, Huber C MAbs. 2022; 14(1):2132977.
PMID: 36239533 PMC: 9578466. DOI: 10.1080/19420862.2022.2132977.
Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases.
Olivera-Ardid S, Bello-Gil D, Tuzikov A, Araujo R, Ferrero-Alves Y, Garcia Figueroa B Front Immunol. 2022; 13:873019.
PMID: 35432370 PMC: 9009260. DOI: 10.3389/fimmu.2022.873019.
Galili U Front Mol Biosci. 2021; 8:746883.
PMID: 34805272 PMC: 8601398. DOI: 10.3389/fmolb.2021.746883.
Galili U Vaccine. 2020; 38(42):6487-6499.
PMID: 32907757 PMC: 7437500. DOI: 10.1016/j.vaccine.2020.08.032.